Comparative Pharmacology
Head-to-head clinical analysis: K 8 versus K LEASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K 8 versus K LEASE.
K+8 vs K-LEASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replenishment; corrects hypokalemia by increasing extracellular potassium concentration, restoring membrane potential and cardiac conduction.
Potassium ion replacement therapy; increases extracellular potassium levels to correct hypokalemia.
40-80 mEq intravenously per day, infusion rate not exceeding 10 mEq/hour; or 20-40 mEq orally 2-4 times daily.
1 tablet (25 mEq) orally 2-4 times daily with meals; maximum 100 mEq/day.
None Documented
None Documented
Terminal elimination half-life ~2-4 hours (shorter with valproate coadministration, prolonged with renal impairment).
Not applicable; exogenous potassium is not subject to terminal elimination half-life as it is rapidly redistributed and excreted. Clinical context: the half-life of redistribution is minutes to hours.
Primarily renal: >90% excreted unchanged by kidneys. Minor fecal (<5%) and negligible biliary elimination.
Excreted renally as potassium chloride; elimination is 100% renal. No biliary or fecal excretion.
Category C
Category C
Potassium Supplement
Potassium Supplement